Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Filtering serum eye drops: does it remove key healing molecules?

NCT ID NCT07407101

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study involved 10 adults with severe dry eye disease who did not respond to standard treatments. Researchers measured levels of growth factors and vitamins in autologous serum eye drops before and after filtration, to see if filtering reduces their concentration. The goal is to help standardize how these drops are made in France.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous serum eye drops
What this could lead to
If successful, this could help standardize the preparation of autologous serum eye drops, potentially improving treatment consistency for severe dry eye disease.
What could go wrong
This is a very small, early-stage study with only 10 participants, focused on lab measurements rather than patient outcomes. Results may not translate to better symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Apr 2026

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adult patients * patients covered by health insurance * patients managed by the Ophtalmology Department of the University Hospital of Limoges * patients diagnosed with dry eyes syndrome, who have not responded to conventionnal treatments * free, informed, written and signed consent Exclusion Criteria: * person incapable of consent * legal guardianship or wardship * patient who does not wish to know the results of serological tests Secondary exclusion criteria: \- a positive serology for at least of of the following agents (HIV, HCV, HBV or syphilis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye syndrome (DES) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye syndrome (DES)

Contacts and locations

Locations

  • CHU Limoges

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.